



Universiteit
Leiden
The Netherlands

Ductal carcinoma in situ of the breast : cancer precursor or not?

Visser, L.L.

Citation

Visser, L. L. (2020, March 10). *Ductal carcinoma in situ of the breast : cancer precursor or not?*. Retrieved from <https://hdl.handle.net/1887/86290>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/86290>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/86290> holds various files of this Leiden University dissertation.

Author: Visser, L.L.

Title: Ductal carcinoma in situ of the breast : cancer precursor or not?

Issue Date: 2020-03-10

List of publications

L.L. Visser, M. Hoogstraat, T. Bismeyer, F. Nieboer, M. de Maaker, P. Kristel, L. Mulder, M. Kreté, W. Brugman, M. Schaapveld, M.K. Schmidt, L.F.A. Wessels, J. Wesseling*, E.H. Lips*, on behalf of the PRECISION team. Deciphering the genomic and epigenomic landscapes of ductal carcinoma in situ associated with and without subsequent invasive breast cancer. *Manuscript in preparation*.

*: Shared last author

L.L. Visser, M. Hoogstraat, T. Bismeyer, F. Nieboer, M. de Maaker, P. Kristel, L. Mulder, M. Kreté, W. Brugman, M. Schaapveld, M.K. Schmidt, E. Sawyer, A. Thompson, A. Futreal, H. Davies, S. Nik-Zainal, L.F.A. Wessels, E.H. Lips*, J. Wesseling*, on behalf of the PRECISION team. Approximately 30% of invasive ipsilateral breast cancers after treatment of ductal carcinoma in situ may be new independent primary cancers. *Manuscript in preparation*.

L.L. Visser, L.E. Elshof, K. van de Vijver, E.J. Groen, M.M. Almekinders, J. Sanders, C. Bierman, D. Peters, I. Hofland, A. Broeks, F.E. van Leeuwen, E.J. Rutgers, M.K. Schmidt, M. Schaapveld, E.H. Lips, J. Wesseling. Discordant marker expression between invasive breast carcinoma and corresponding synchronous and preceding DCIS. *Am J Surg Pathol*. 2019 Nov;43(11):1574-1582. doi: 10.1097/PAS.0000000000001306.

L.L. Visser, E.J. Groen, F. E. van Leeuwen, E.H. Lips, M.K. Schmidt*, and J. Wesseling*. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. *Cancer Epidemiol Biomarkers Prev*. 2019 May;28(5):835-845. doi: 10.1158/1055-9965.

L.L. Visser, L.E. Elshof, M. Schaapveld, K. Van de Vijver, E.J. Groen, M.M. Almekinders, C. Bierman, F.E. van Leeuwen, E.J. Rutgers, M.K. Schmidt, E.H. Lips, J. Wesseling. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ. *Clin Cancer Res*. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.

Not in this thesis:

E.J. Groen, L.E. Elshof, L.L. Visser, E.J. Rutgers, G.H.A. Winter-Warnars, E.H. Lips, J. Wesseling. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). *Breast*. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001.

Appendices

J.M. Ruben, L.L. Visser, K.M. Heinhuis, T. O'Toole, H.J. Bontkes, T.M. Westers, G.J. Ossenkoppele, T.D. de Gruijl, A.A. van de Loosdrecht. A human cell line model for interferon- α driven dendritic cell differentiation. *PLoS One*. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219.

S. Ariotti, M.A. Hogenbirk, F.E. Dijkgraaf, L.L. Visser, M.E. Hoekstra, J. Song, H. Jacobs, J.B. Haanen, T.N. Schumacher. Induction of tissue-wide pathogen alert upon skin-resident memory CD8⁺ T cell triggering. *Science*. 2014 Oct 3;346(6205):101-5. doi: 10.1126/science.1254803.

J.M. Ruben, L.L. Visser, H.J. Bontkes, T.M. Westers, G.J. Ossenkoppele, T.D. de Gruijl, A.A. van de Loosdrecht. Targeting the leukemic stem cell compartment by enhancing tumor cell-based vaccines. *Immunotherapy*. 2013 Aug;5(8):859-68. doi: 10.2217/imt.13.76.

About the author

Lindy Larissa Visser was born on October 23th, 1989 in Alkmaar. She graduated from secondary education (HAVO) in 2007 at Christelijke Scholengemeenschap Jan Arentsz. Subsequently, she enrolled the Biology and Medical Laboratory Research program at the University of Applied Sciences in Leiden, with a major in cytology and histopathology. Triggered by her interest in oncology, she performed her research internship in the field of oncology. After obtaining her bachelor degree in 2011, she continued with a Master's program in Oncology, during which she participated in several courses on medical oncology, tumor immunology, and research ethics. She performed her first internship in the lab of prof. dr. Arjan A. van de Loosdrecht at the VU University Medical Center – Cancer Center Amsterdam (CCA). Her second internship was carried out at the Netherlands Cancer Institute in the lab of prof. dr. Ton N.M. Schumacher. Both internships were focused on tumor immunology. She obtained her master's degree in 2013. On May 15th, 2014 she joined the group of prof. dr. Jelle Wesseling as a graduate student, where she conducted the research described in the current thesis. In 2018, Lindy received the AACR-Pezcollor Scholar-In-Training Award 2018 for her work on molecular changes associated with progression of DCIS to subsequent invasive breast cancer. That same year, she also was awarded with the PALGA-prijs, a prize for the best research project making use of data from the Dutch cytopathology and histopathology registry (PALGA). July 1st, 2019 Lindy continued her work in the direction of molecular and computational biology within the single cell genomics team of prof. dr. Frank C.P. Holstege at the Prinsess Máxima Center for pediatric oncology.